# Simone Botti

> Simone Botti is a Series B investor at Metabomed (Rehovot) backing Biotechnology and Biopharma. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Metabomed](https://shizune.co/investors/profile/metabomed)
- Location: Rehovot, Israel
- Total investments: 4
- Last investment: May 2023
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/simonebotti
- X (Twitter): https://twitter.com/simobotti
- Website: https://x.com/simobotti

Simone Botti is a Venture Partner at Matar Capital Advisors Ltd. He serves as Chief Executive Officer of Metabomed LTD. Simone Botti is currently employed at Merck Serono S.A., Investment Arm. He was the Vice President of Business Development at RAD BioMed Accelerator. He joined RAD BioMed Accelerator in November 2008. He regularly acts as aconsultant for major European and Asian governments and financial institutions in matters of technology transfer and technology financing. He has a successful ten year career of life science entrepreneur, business development professional, and consultant. Prior to Matar Capital Advisors, he was the Founder and Managing Partner at Altiora Ventures a Corporate Finance and Investment Banking Boutique specialized in cross border M&A and international business development. Simone Botti was also a Senior Director, Business Development (EMEA) for Cogenics. He was the Chief Executive Officer and Chief Scientist at BioStrX Ltd. He also co-founded the firm. He was a Vice President at SIXX Partners. Simone Botti was a Councilor of the Italian-Israeli Chamber of Commerce and a founding member of the Israel-Asia Chamber of Commerce. In this capacity, he organized a number of high-level conferences on technology transfer between Israel and several European and Asian countries. He is Senior Consultant to the Israel Structural Proteomics Center at the Weizmann Institute of Science, and a member of the Biophysical Society. He was NIH–ADDP Fellow at Northwestern University Medical School in Chicago. He received the “Dov Elad“ award in Structural Biology. Simone Botti holds a Ph.D. Chemistry from the Weizmann Institute of Science.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Biopharma | 1 | 25% |
| Life Science | 1 | 25% |
| Therapeutics | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Seed | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 25% |
| Germany | 1 | 25% |
| The Netherlands | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Anavo Therapeutics | Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $9.4M | Seed | May 02, 2023 |  |
| Precirix | Developing radio-immunotherapeutic drugs for cancer patients. | $88.2M | Series B | Mar 16, 2022 |  |
| Cardior Pharmaceuticals | Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress orinjury.Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world. | $75.3M | Series B | Aug 25, 2021 |  |
| Anavo Therapeutics | Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $24M | Seed | Apr 22, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 2 deals together
- [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures) — VC Fund, 2 deals together
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 2 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 2 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together

## About Metabomed

VC Fund · Yavne, Israel

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

1 contacts available at Metabomed.

| Name | Title | Profile |
| --- | --- | --- |
| Simone Botti | CEO | https://shizune.co/investors/profile/simone-botti |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Simone Botti invest in?

Simone Botti invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series B and Seed stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Simone Botti last invest?

The most recent investment recorded for Simone Botti closed in May 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co